Diffuse Large B-cell Lymphoma Archives - Page 10 of 10

Denosumab has robust clinical efficacy in the treatment of patients with giant cell tumor of bone.

Concordant Bone Marrow Involvement May Lead to Worse Outcomes in DLBCL

By

July 12, 2017

Concordant BM involvement in patients diagnosed with diffuse large B cell lymphoma is associated with worse clinical outcomes.

Cutaneous adverse events while receiving pembrolizumab has been linked with better treatment respons

Lymphoma

Rituximab for DLBCL May Double Risk of Subsequent AML

By

Jonathan Goodman, MPhil

May 25, 2017

Rituximab’s mechanism of action may reduce immune surveillance, allowing for the proliferation of cancer cells and infectious agents.

Patients who are treated for multiple myeloma at high-volume cancer centers have better survival out

Lymphoma

Patients With DLBCL at Elevated Risk of Non-cancer-related Death

By

Jonathan Goodman, MPhil

May 3, 2017

Patients with DLBCL were at an increased risk of non-cancer-related deaths from blood disease, infection, gastrointestinal disease, vascular diseases, and lung disease.

Patients with metastatic renal cell carcinoma who transitioned to a modified 2/1 schedule of sunitin

Lymphoma

Lenalidomide Prolongs PFS Among Elderly Patients With DLBCL

By

Andrea S. Blevins Primeau, PhD, MBA

April 21, 2017

Data suggest that lenalidomide maintenance for 24 months can prolong PFS among elderly patients with DLBCL, but does not improve overall survival.

Researchers are identifying new roles for infectious and commensal microbes in facilitating and inhi

Lymphoma

Single-nucleotide Polymorphisms Predict Response to R-CHOP in DLBCL

By

Jonathan Goodman, MPhil

March 30, 2017

Two SNPS (rs4880 and rs1870377) had an association with PFS among patients with DLBCL receiving R-CHOP.

Selinexor represents a much-needed therapeutic addition to the available agents for the treatment of

Lymphoma

Steroid-containing Chemotherapy Can Induce Diabetes in DLBCL

By

Andrea S. Blevins Primeau, PhD, MBA

March 30, 2017

Glucocorticoid-containing chemotherapy may induce diabetes mellitus or worsen glucose control among patients with diffuse large B cell lymphoma.

Lymphoma

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

By

Jason Hoffman, PharmD, RPh

February 22, 2017

Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.

Drugmaker funding for patient advocacy groups might be an important but neglected factor in rising d

Lymphoma

Event-free Survival at 24 Months as a Surrogate Endpoint for DLBCL

By

Leah Lawrence

January 18, 2017

Patients with diffuse large B-cell lymphoma (DLBCL) who achieved post-treatment event-free survival for 24 months had only a minimally lower life expectancy.

Lymphoma